

Chapter 229

Antihistamines

Robert A. Wood

REFERENCES

1. Leurs R, Church MK, Tagliabue M: H₁-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. *Clin Exp Allergy* **32**:489, 2002 [PMID: 11972592]
2. Simons FE: Advances in H₁-antihistamines. *N Engl J Med* **351**:2203, 2004 [PMID: 15548781]
3. Passalacqua G, Canonica GW: Structure and classification of H₁-antihistamines and overview of their activities. In: *Histamine and H₁-Antihistamines in Allergic Disease*, 2nd edition, edited by FER Simons. New York, Marcel Dekker, 2002, p. 65
4. Jinquan T et al: Cetirizine inhibits the in vitro and ex vivo chemotactic response of T lymphocytes and monocytes. *J Allergy Clin Immunol* **95**:979, 1995 [PMID: 7751519]
5. Marone G et al: Antiinflammatory effects of oxatomide. *J Invest Allergol Clin Immunol* **9**:207, 1999 [PMID: 10513346]
6. el-Shazly AE et al: Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate. *Immunopharmacol Immunotoxicol* **18**:587, 1996 [PMID: 8933171]
7. Aguawal DK et al: Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation. *Allergy* **55**(Suppl. 63):276, 2000
8. Simons FER, Simons KJ: Clinical pharmacology of H₁-antihistamines. In: *Histamine and H₁-Antihistamines in Allergic Disease*, 2nd edition, edited by FER Simons. New York, Marcel Dekker, 2002, p. 141
9. Jansen B et al: Pharmacokinetics and pharmacodynamics of the novel H₁-receptor antagonist emedastine in healthy volunteers. *Eur J Clin Pharmacol* **55**:837, 2000 [PMID: 10805062]
10. Deschamps C et al: Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model. *Clin Pharmacol Ther* **68**:647, 2000 [PMID: 11180025]
11. Grant JA et al: A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: Suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. *Ann Allergy Asthma Immunol* **88**:190, 2002 [PMID: 11868924]
12. Devalia JL et al: A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. *Allergy* **56**:50, 2001 [PMID: 11167352]
13. Cetirizine. In: *DRUGDEX System*. Greenwood Village, CO, Thomson Micromedex [updated periodically], <http://www.thomsonhc.com/hcs/librarian>
14. Geha RS, Meltzer EO: Desloratadine: A new, non-sedating, oral antihistamine. *J Allergy Clin Immunol* **107**:751, 2001 [PMID: 11295678]
15. Breneman D et al: Cetirizine and astemizole therapy for chronic idiopathic urticaria: A double-blind, placebo-controlled comparative trial. *J Am Acad Dermatol* **33**:192, 1995 [PMID: 7622644]
16. Ring J et al: Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. *Int J Dermatol* **40**:1, 2001
17. Leynadier F, Duarte-Risselin C, Murrieta M: Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria: URTILOR study group. *Eur J Dermatol* **10**:205, 2000 [PMID: 10725819]
18. Lorette G et al: One-year treatment of chronic urticaria with mizolastine: Efficacy and safety. URTOL study group. *J Eur Acad Dermatol Venereol* **14**:83, 2000 [PMID: 10972091]
19. Camarasa JM et al: Azelastine tablets in the treatment of chronic idiopathic urticaria: Phase III, randomised, double-blind, placebo and active controlled multicentric clinical trial. *Skin Pharmacol Appl Skin Physiol* **14**:77, 2001 [PMID: 11316966]
20. LaRosa M et al: Double-blind multicenter study on the efficacy and tolerability of cetirizine compared to oxatomide in chronic idiopathic urticaria in preschool children. *Ann Allergy Asthma Immunol* **87**:48, 2001
21. Breneman DL: Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. *Ann Pharmacother* **30**:1075, 1996 [PMID: 8893110]

22. Potter PC et al: Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. *Allergy* **64**:596, 2009. [PMID: 19053988]
23. Handa S, Dogra S, Kumar B: Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. *J Dermatolog Treat* **15**:55, 2004 [PMID: 14754652]
24. Garg G, Thami GP: Comparative efficacy of cetirizine and levocetirizine in chronic idiopathic urticaria. *J Dermatolog Treat* **18**:23, 2007 [PMID: 17365263]
25. Diepgen TL: Early Treatment of the Atopic Child Study Group: Long-term treatment with cetirizine of infants with atopic dermatitis: A multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. *Pediatr Allergy Immunol* **13**:278, 2002 [PMID: 12390444]
26. Klein PA, Clark RAF: An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. *Arch Dermatol* **135**:1522, 1999 [PMID: 10606058]
27. Tefferi A, Pardanani A: Clinical, genetic, and therapeutic insights into systemic mast cell disease. *Curr Opin Hematol* **11**:58, 2004 [PMID: 14676628]
28. Frieri M, Alling DW, Metcalfe DD: Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. *Am J Med* **78**:9, 1985 [PMID: 3917606]
29. Friedman BS et al: Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis. *J Allergy Clin Immunol* **92**:520, 1993 [PMID: 8104966]
30. Summey BT, Yosipovitch: Pharmacologic advances in the systemic treatment of itch. *Dermatol Ther* **18**:328, 2005 [PMID: 16297005]
31. Zuberbier T et al: EAACI/GA(2)LEN/EDF/WAO guideline: Management of urticaria. *Allergy* **64**:1427, 2009 [PMID: 19772513]
32. Powell RJ et al: BSACI guidelines for the management of chronic urticaria and angio-oedema. *Clin Exp Allergy* **37**:631, 2007 [PMID: 17456211]
33. Asero R: Chronic unremitting urticaria: Is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. *Clin Exp Dermatol* **32**:34, 2007 [PMID: 17042777]
34. Cyproheptadine. In: *DRUGDEX System*, Greenwood Village, CO, Thomson Micromedex [updated periodically], <http://www.thomsonhc.com/hcs/librarian>
35. Casale TB et al: First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. *J Allergy Clin Immunol* **111**:S835, 2003
36. Lauria JI, Markello R, King BD: Circulatory and respiratory effects of hydroxyzine in volunteers and geriatric patients. *Anesth Analg* **47**:378, 1968 [PMID: 5690527]
37. Horak F, Stübner UP: Comparative tolerability of second generation antihistamines. *Drug Saf* **20**:385, 1999 [PMID: 10348091]
38. Aaronson DW: Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. *Ann Allergy Asthma Immunol* **76**:440, 1996 [PMID: 8630718]
39. Mansmann HC Jr. et al: Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. *Ann Allergy* **68**:348, 1992 [PMID: 1348405]
40. Leyh F et al: A comparison of acrivastine versus clemastine and placebo in the treatment of patients with chronic idiopathic urticaria. *J Int Med Res* **17**(Suppl. 2):22B, 1989
41. Mann RD et al: Sedation with "non-sedating" antihistamines: Four prescription-event monitoring studies in general practice. *BMJ* **320**:1184, 2000 [PMID: 10784544]
42. Hamelin BA et al: In vitro characterization of cytochrome P450 206 inhibition by classic histamine H₁ receptor antagonists. *Drug Metab Dispos* **26**:536, 1998 [PMID: 9616188]
43. Hamelin BA et al: Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with the high or low CYP2D6 activity. *Clin Pharmacol Ther* **67**:466, 2000 [PMID: 10824625]
44. Lessard E et al: Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. *J Clin Psychopharmacol* **87**:48, 2001
45. Gilbert C et al: Fetal safety of drugs used in the treatment of allergic rhinitis: A critical review. *Drug Saf* **28**:707, 2005 [PMID: 16048356]
46. Seto A, Einarson T, Koren G: Pregnancy outcome following first trimester exposure to antihistamines: Meta-analysis. *Am J Perinatol* **14**:119, 1997 [PMID: 9259911]
47. Pastuszak A et al: The safety of astemizole in pregnancy. *J Allergy Clin Immunol* **98**:748, 1996 [PMID: 8876549]
48. Cimetidine. In: *DRUGDEX System*. Greenwood Village, CO, Thomson Micromedex [updated periodically], <http://www.thomsonhc.com/hcs/librarian>

49. Ranitidine. In: *DRUGDEX System*. Greenwood Village, CO, Thomson Micromedex, [updated periodically], <http://www.thomsonhc.com/hcs/librarian>
50. Famotidine. In: *DRUGDEX System*. Greenwood Village, CO, Thomson Micromedex [updated periodically] <http://www.thomsonhc.com/hcs/librarian>
51. Nizatidine. In: *DRUGDEX System*. Greenwood Village, CO, Thomson Micromedex, updated periodically, <http://www.thomsonhc.com/hcs/librarian>
52. Simons FE, Sussman GL, Simons KJ: Effect of the H₂-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H₁-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. *J Allergy Clin Immunol* **95**:685, 1995 [PMID: 7897151]
53. Bleehen SS et al: Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: A multi-centre randomized double-blind study. *Br J Dermatol* **117**:81, 1987 [PMID: 3307890]
54. Weick JK et al: The use of cimetidine for the treatment of pruritus in polycythemia vera. *Arch Intern Med* **142**:241, 1982 [PMID: 7059251]
55. Wilkin JK, Rountree CB: Blockade of carcinoid flush with cimetidine and clonidine. *Arch Dermatol* **118**:109, 1982 [PMID: 7059211]
56. Leman JA, Benton EC: Verrucas. Guidelines for management. *Am J Clin Dermatol* **1**:143, 2000 [PMID: 11702295]
57. Drayer DE et al: Age and renal clearance of cimetidine. *Clin Pharmacol Ther* **31**:45, 1982 [PMID: 753303]
58. Yamreudeewong W et al: Potentially significant drug interactions of class III antiarrhythmic drugs. *Drug Saf* **26**:421, 2003 [PMID: 12688833]
59. Gafter U et al: Thrombocytopenia associated with hypersensitivity to ranitidine: Possible cross-reactivity with cimetidine. *Am J Gastroenterol* **84**:560, 1989 [PMID: 2719014]
60. Sonnenblick M, Yinnon A: Mental confusion as a side effect of ranitidine [letter]. *Am J Psychiatry* **2**:257, 1986
61. Laheij RJF et al: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. *JAMA* **292**:1955, 2004 [PMID: 15507580]
62. Jensen RT et al: Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. *N Engl J Med* **308**:883, 1983 [PMID: 6835285]
63. Tullio CJ, Roberts MA: Cimetidine-induced alopecia. *Clin Pharm* **4**:145, 1985 [PMID: 3987212]
64. Nault MA, Milne B, Parlow JL: Effects of the selective H₁ and H₂ histamine receptor antagonists loratadine and ranitidine on autonomic control of the heart. *Anesthesiology* **96**:336, 2002 [PMID: 11818765]
65. Guillet R et al: Association of H₂-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. *Pediatrics* **117**:e137, 2006
65. Black AK, Greaves MW: Antihistamines in urticaria and angioedema. In: *Histamine and H₁-Antihistamines in Allergic Disease*, 2nd edition, edited by FER Simons. New York, Marcel Dekker, 2002, p. 249
65. Greaves MW: Itch in systemic disease: Therapeutic options. *Dermatol Ther* **18**:323, 2005 [PMID: 16297004]
66. Greene SL, Reed CE, Schroeter AL: Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. *J Am Acad Dermatol* **12**:669, 1985 [PMID: 3886724]
69. Drake LA, Fallon JD, Sober A: Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. *J Am Acad Dermatol* **31**:613, 1994 [PMID: 8089287]
70. Doxepin. In: *DRUGDEX System*. Greenwood Village, CO, Thomson Micromedex [updated periodically] <http://www.thomsonhc.com/hcs/librarian>
71. Egan C, Rallis TM: Treatment of chronic urticaria with ketotifen. *Arch Dermatol* **133**:147, 1997 [PMID: 9041826]
72. Phanuphak P: Double-blind, placebo-controlled study of ketotifen in chronic urticaria. *Immunol Allerg Pract* **9**:138, 1987
73. Mansfield LE et al: Inhibition of dermatographia, histamine, and dextromethorphan skin tests by ketotifen. A possible effect on cutaneous vascular response to mediators. *Ann Allergy* **63**:201, 1989 [PMID: 2774302]
74. Kamide R et al: Clinical evaluation of ketotifen for chronic urticaria: Multicenter double-blind comparative study with clemastine. *Ann Allergy* **62**:322, 1989 [PMID: 2650586]
75. Riccardi VM: Mast-cell stabilization to decrease neurofibroma growth. Preliminary experience with ketotifen. *Arch Dermatol* **123**:1011, 1987 [PMID: 3115189]
76. Ketotifen. In: *DRUGDEX System*. Greenwood Village, CO, Thomson Micromedex [updated periodically] <http://www.thomsonhc.com/hcs/librarian>

